DR5 antibodies and uses thereof
First Claim
Patent Images
1. An anti-DR5 antibody comprising at least one mutation in the heavy and/or light chain of full-length antibody 16E2 (SEQ ID NOS:
- 11 and 13, respectively), or a fragment thereof, wherein said antibody or antibody fragment has a greater affinity for DR5 than said full-length antibody 16E2, and/or exhibits a greater biological activity and/or potency than said full-length antibody 16E2.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
-
Citations
76 Claims
-
1. An anti-DR5 antibody comprising at least one mutation in the heavy and/or light chain of full-length antibody 16E2 (SEQ ID NOS:
- 11 and 13, respectively), or a fragment thereof, wherein said antibody or antibody fragment has a greater affinity for DR5 than said full-length antibody 16E2, and/or exhibits a greater biological activity and/or potency than said full-length antibody 16E2.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)
-
52. Isolated nucleic acid encoding the heavy or light chain of Apomab 7.3 or Apomab 8.3.
Specification